文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺放疗中神经血管束剂量最小化的挑战与机遇

Challenges and opportunities to minimize the dose in the neurovascular bundles during prostate radiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-04-09

本研究对20例局限性前列腺癌患者回顾性勾画神经血管束(NVB),使用Erasmus-iCycle自动生成5×7.25 Gy计划,比较非NVB保护、不牺牲靶区覆盖的NVB保护及允许靶区欠剂量的NVB保护方案。不牺牲覆盖的NVB保护显著降低NVB D0.1 cc和Dmean,进一步降低NVB剂量与靶区覆盖降低相关,非共面计划在相似NVB D0.1 cc下靶区覆盖更高但无临床相关获益。

要点

  • 不牺牲靶区覆盖的NVB保护计划可行,显著降低NVB D0.1 cc和Dmean。
  • 进一步降低NVB D0.1 cc与靶区覆盖降低明确相关,可用Pareto前沿权衡。
  • 非共面计划在相似NVB D0.1 cc下靶区覆盖更高,但无临床相关获益。

核心结论

  • 不牺牲靶区覆盖的NVB保护是可行的。
  • 非共面NVB保护计划虽总体统计学更优,但相比共面计划未发现临床相关获益。
  • 进一步保护NVB以靶区覆盖为代价,Pareto前沿可作为临床实践工具。

研究设计与样本

  • 对20例既往接受治疗的限制性前列腺癌患者,基于MRI-CT匹配回顾性勾画NVB。
  • 所有计划(5×7.25 Gy)使用Erasmus-iCycle自动生成,比较共面与非共面束流布置。
  • 不牺牲覆盖的NVB保护(u-NVBsparing)与非NVB保护(non-NVBsparing)比较,允许靶区欠剂量的NVB保护(c-NVBsparing)以Pareto前沿展示。
  • 统计显著性(p值<0.05)由Wilcoxon符号秩检验确定。

主要发现

  • u-NVBsparing相比non-NVBsparing,共面计划NVB D0.1 cc中位数38.9 vs 42.6 Gy,Dmean中位数25.6 vs 30.0 Gy,均显著降低。
  • u-NVBsparing相比non-NVBsparing,非共面计划NVB D0.1 cc中位数38.9 vs 43.3 Gy,Dmean中位数24.7 vs 30.2 Gy,均显著降低。
  • c-NVBsparing计划中进一步降低NVB D0.1 cc与靶区覆盖降低明确相关。
  • 非共面c-NVBsparing计划在相似NVB D0.1 cc值下,靶区覆盖显著高于共面计划。

关键数值与推荐

  • NVB D0.1 cc:u-NVBsparing共面38.9 Gy vs non-NVBsparing共面42.6 Gy。
  • NVB D0.1 cc:u-NVBsparing非共面38.9 Gy vs non-NVBsparing非共面43.3 Gy。
  • NVB Dmean:u-NVBsparing共面25.6 Gy vs non-NVBsparing共面30.0 Gy。
  • NVB Dmean:u-NVBsparing非共面24.7 Gy vs non-NVBsparing非共面30.2 Gy。
  • 计划剂量为5×7.25 Gy,统计显著性阈值为p值<0.05。

临床怎么用

  • NVB保护可在不牺牲靶区覆盖的情况下实现。
  • 进一步降低NVB剂量需权衡靶区覆盖,Pareto前沿可作为临床实践工具。
  • 非共面计划虽统计学更优,但未发现临床相关获益。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Radiation damage to the neurovascular bundles (NVB) has been linked to erectile dysfunction after prostate cancer radiotherapy (PCa). NVB sparing using coplanar and non-coplanar automated treatment planning is presented here in two settings: (1) without compromising target coverage, (2) allowing target coverage compromise. MATERIAL AND METHODS: 20 previously treated patients with localized PCa. Based on a MRI-CT match, the NVB were retrospectively delineated. All treatment plans (5 × 7.25 Gy) were automatically generated using Erasmus-iCycle (in-house automated treatment planning algorithm). Non-NVB sparing (non-NVBsparing) plans and NVB sparing plans in two settings were generated: (1) uncompromised NVB sparing (u-NVBsparing; maintaining target coverage) (2) and compromised NVB sparing (c-NVBsparing; allowing target underdosage). Coplanar and non-coplanar beam arrangements were compared. U-NVBsparing was compared to non-NVBsparing. C-NVBsparing plans were visualized in Pareto fronts. Statistical significance (p-value < 0.05) was determined by Wilcoxon signed-rank test. RESULTS: u-NVBsparing compared to non-NVBsparing plans showed statistically significant median reductions in NVB D0.1 cc (38.9 vs 42.6 Gy for coplanar; 38.9 vs 43.3 Gy for non-coplanar) and Dmean (25.6 vs 30.0 Gy for coplanar; 24.7 vs 30.2 Gy for noncoplanar). Further lowering NVB D0.1 cc in c-NVBsparing plans clearly correlated to lower target coverage. Non-coplanar c-NVBsparing plans maintained significantly higher target coverages for similar NVB D0.1 cc values, compared to coplanar plans. CONCLUSION: NVB sparing without compromising target coverage is feasible. No clinically relevant benefit was found for non-coplanar compared to coplanar NVB sparing plans, although overall statistically superior. Further sparing of the NVB comes at the cost of target coverage, for which a Pareto front could be used as a tool in clinical practise.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Brand VJ, Rossi L, Milder MTW, et al. Challenges and opportunities to minimize the dose in the neurovascular bundles during prostate radiotherapy. Clin Transl Radiat Oncol. 2025. PMID: 40270948. doi:10.1016/j.ctro.2025.100959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。